Board of Directors

Hans is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme and Organon. He served on the boards of amongst others Hansa Biopharma, Wilson Therapeutics (acquired by Alexion), Sobi, Therachon (acquired by Pfizer) and VectivBio (acquired by Ironwood).

Share awards and RSUs: 152.182

Shareholdings: View shareholding

Education: Pharmacist degree (PharmD) from the University of Utrecht.

Other assignments: Chairman of Microbiotica Ltd, Vice chairman of Pharvaris NV, supervisory board member of Organon NV. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.

Jacob is CFO and Co-founder of Purpose Pharma and a former partner at HealthCap. He has extensive experience in venture capital investments and investment banking related to the life sciences sector. Jacob Gunter­berg has long experience as board member in both private and publicly traded companies.

Share awards and RSUs: 72.675

Shareholdings: View shareholding

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments: Chairman and CFO in Purpose Pharma AB, Board member in Aurelia Invest AB, EllAug AB, Tova Skrenen Stockholm AB and Twiceme Technology Sweden AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Shareholdings: View shareholding

Share awards and RSUs:

Education: Master’s Degree in Physical Education from the Faculty of Medicine and Health Sciences of the University of Ghent.

Other assignments: Board member of Ipsen and an industry advisor to private equity firms.

Independent of the company and its senior management and independent of major shareholders of the company.

Heidi has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution. Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.

Share awards and RSUs: 73.605

Shareholdings: View shareholding

Education: M.B.A., Marketing and International Business, The University of Chicago. B.A., Economics and German, Magna cum laude, The University of Michigan

Other assignments: Board member Bavarian Nordic, IO Biotech and Sutro Biopharma.

Independent of the company and its senior management and independent of major shareholders of the company.

Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. Elisabeth Björk has been the Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca leading the global development of medicines within this area since 2012. Throughout her career at AstraZeneca, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan) and commercial strategy/implementation.

Share awards and RSUs: 73.605

Shareholdings: View shareholding

Education: MD, Karolinska Institute and Ph.D. in Endocrinology, Uppsala University

Other assignments: Board member of Pharvaris N.V., Agi­ana Pharma AS, Rocket Pharmaceuticals, Inc., Camurus AB, Hansa BioPharma AB and Betula Consulting AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Ann has more than 25 years of drug discovery and development experience in the pharmaceutical and biotech worlds. She has contributed to several approved drugs and has worked in the rare disease, neuropsychiatry and pulmonology fields.

Share awards and RSUs: 73.605

Shareholdings: View shareholding

Education: MD, PhD.

Other assignments: Board member of Pieris Pharmaceuticals

Independent of the company and its senior management and independent of major shareholders of the company.

Yasir is a seasoned executive, board member, and strategic advisor to biotech companies. He is currently CEO of Vesalius Therapeutics and CEO Partner at Flagship Pioneering. Yasir has had operational experience running finance and business development functions at both public and private biotech companies, and prior to that had senior roles in investment banking both as an equity analyst and in corporate finance.

Share awards and RSUs: 52.744

Shareholdings: View shareholding

Education:  BM BCh.

Other assignments: Board member of Maxcyte and Vesalius.

Independent of the company and its senior management and independent of major shareholders of the company.